Privacy Policy

Who we are

Suggested text: Our website address is: https://resolventx.com.

Comments

Suggested text: When visitors leave comments on the site we collect the data shown in the comments form, and also the visitor’s IP address and browser user agent string to help spam detection.

An anonymized string created from your email address (also called a hash) may be provided to the Gravatar service to see if you are using it. The Gravatar service privacy policy is available here: https://automattic.com/privacy/. After approval of your comment, your profile picture is visible to the public in the context of your comment.

Media

Suggested text: If you upload images to the website, you should avoid uploading images with embedded location data (EXIF GPS) included. Visitors to the website can download and extract any location data from images on the website.

Cookies

Suggested text: If you leave a comment on our site you may opt-in to saving your name, email address and website in cookies. These are for your convenience so that you do not have to fill in your details again when you leave another comment. These cookies will last for one year.

If you visit our login page, we will set a temporary cookie to determine if your browser accepts cookies. This cookie contains no personal data and is discarded when you close your browser.

When you log in, we will also set up several cookies to save your login information and your screen display choices. Login cookies last for two days, and screen options cookies last for a year. If you select "Remember Me", your login will persist for two weeks. If you log out of your account, the login cookies will be removed.

If you edit or publish an article, an additional cookie will be saved in your browser. This cookie includes no personal data and simply indicates the post ID of the article you just edited. It expires after 1 day.

Embedded content from other websites

Suggested text: Articles on this site may include embedded content (e.g. videos, images, articles, etc.). Embedded content from other websites behaves in the exact same way as if the visitor has visited the other website.

These websites may collect data about you, use cookies, embed additional third-party tracking, and monitor your interaction with that embedded content, including tracking your interaction with the embedded content if you have an account and are logged in to that website.

Who we share your data with

Suggested text: If you request a password reset, your IP address will be included in the reset email.

How long we retain your data

Suggested text: If you leave a comment, the comment and its metadata are retained indefinitely. This is so we can recognize and approve any follow-up comments automatically instead of holding them in a moderation queue.

For users that register on our website (if any), we also store the personal information they provide in their user profile. All users can see, edit, or delete their personal information at any time (except they cannot change their username). Website administrators can also see and edit that information.

What rights you have over your data

Suggested text: If you have an account on this site, or have left comments, you can request to receive an exported file of the personal data we hold about you, including any data you have provided to us. You can also request that we erase any personal data we hold about you. This does not include any data we are obliged to keep for administrative, legal, or security purposes.

Where your data is sent

Suggested text: Visitor comments may be checked through an automated spam detection service.

Jim Russell, MD. - Co-Founder and Board Chair

Dr. Russell has 43 years experience doing research on severe infections. His main focus has been discovery of biomarkers and novel therapeutics.  Dr. Russell has pivoted to research on community-acquired pneumonia (CAP), the commonest cause of sepsis, a more homogeneous condition than sepsis for mechanistic and drug discovery.  He was a founder of Sirius Genomics and Cyon Therapeutics. He is the #1 global expert in septic shock research (Expertscape; 326 publications. H index 93). He has led trials in septic shock and COVID-19, and during and after the COVID pandemic he secured $7M CIHR, St. Paul’s Foundation and other funding for the CAPtivate program (27 publications) and has raised $23.5M as a co-investigator. He has extensive experience with murine and human sepsis and was a co-discoverer of the central role of PCSK9 in severe infections.

This will close in 0 seconds

Ehsan Ansari Dezfouli, PhD. - Senior Scientist, Mitacs Postdoctoral Fellow

Dr. Dezfouli is a nanomedicine researcher with over 10 years of experience in formulation and drug development, having worked on LNP mRNA COVID-19 vaccines and in vivo CAR-T applications. He also has over 5 years of industrial experience in nanomedicine development and is currently working as a post-doctoral fellow in the labs of Dr. Russell and Cullis to develop LNP RNA drugs for severe acute infections. Dr. Dezfouli is working as lead scientist in the lab.

This will close in 0 seconds

Cedric Brimacombe, PhD. - Co-Founder, VP BD

Dr. Brimacombe is a synthetic biologist with extensive experience in infectious disease and bacterial and fungal genetics and has worked as a lead researcher in both Academia and Industry for over 15 years. In 2017 he established the Molecular Biology lab at Renaissance BioScience and ran a successful program of RNAi research and development for over 4.5 years as the molecular scientific lead. He also made key contributions to several widely sold industrial yeast products. He later moved to Polymorphic BioScience Inc. in a Business Development position working in the LNP space and has played a leading role in acquiring ~$43 million in government grants for academic and industrial projects. Further, he has lead efforts in developing, funding, and initiating several new projects in LNP RNA space, and manages multiple partnerships and smaller research groups.

This will close in 0 seconds

Pieter Cullis, PhD. - Co-founder

Dr. Cullis has over 40 years of experience in drug development and commercialization. Most notably, Dr. Cullis played an essential role in driving the creation of LNP technology, an essential component of the FDA-approved drugs Onpattro® and Comirnaty® (the Pfizer/BioNTech SARS-CoV-2 vaccine) for which he has received many prestigious awards. Dr. Cullis has extensive experience bringing drugs from concept to clinical application using lipid-based carriers. To this end, he has co-founded more than 12 companies including Acuitas Therapeutics, Precision Nanosystems, Integrated Nanotherapeutics, and NanoVation Therapeutics, among others. He provides strong leadership and advisory experience. Dr. Cullis has played a key role in bringing 5 nanomedicines from basic research labs to clinical application and provides unmatched guidance and a vast network in this regard.

This will close in 0 seconds

Evan Haney, PhD - Director of Operations

Dr. Haney is a biochemist with over 20 years experience across the fields of microbiology, immunology and structural biology and has worked in both academia and industry settings developing novel anti-infective agents and molecular diagnostics assays. In 2021, he joined Asep Medical Inc. as Chief Scientific Officer where he led teams designing novel peptide-based therapeutics targeting bacterial biofilms and spearheaded the development of an innovative blood-based diagnostic test for sepsis. He is a highly productive scientist with over 50 publications, is an inventor on three patents and has given numerous presentations at conferences around the world.

This will close in 0 seconds

Scroll to Top